USask’s VIDO announces positive Phase 1 results for COVAC-2


VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask’s VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.


Share on linkedin
Share on reddit
Share on facebook
Share on twitter
Share on email